Medical technology company Hologic (NASDAQ: HOLX) will be reporting results tomorrow after the bell. Here’s what investors should know.
Hologic met analysts’ revenue expectations last quarter, reporting revenues of $1.02 billion, flat year on year. It was an ok quarter for the company, with revenue guidance for next quarter meeting analysts’ expectations.
Is Hologic a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting Hologic’s revenue to decline 1.6% year on year to $1.00 billion, in line with its flat revenue from the same quarter last year. Adjusted earnings are expected to come in at $1.02 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Hologic has missed Wall Street’s revenue estimates twice over the last two years.
Looking at Hologic’s peers in the healthcare equipment and supplies segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Penumbra delivered year-on-year revenue growth of 16.3%, beating analysts’ expectations by 2.7%, and Boston Scientific reported revenues up 20.9%, topping estimates by 2%. Penumbra traded up 7.2% following the results while Boston Scientific was also up 6.5%.
Read our full analysis of Penumbra’s results here and Boston Scientific’s results here.
Debates over possible tariffs and corporate tax adjustments have raised questions about economic stability in 2025. While some of the healthcare equipment and supplies stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.6% on average over the last month. Hologic is down 4.7% during the same time and is heading into earnings with an average analyst price target of $75.40 (compared to the current share price of $58.50).
When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.
